NCT01889836View on ClinicalTrials.gov

Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Meningitis, Meningococcal, Serogroup C

Interventions

BIOLOGICAL

'MenCC-Bio'

The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.

BIOLOGICAL

MENJUGATE

The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.

Trial Locations (1)

21040-360

Unidade de Ensaios Clínicos para Imunobiológicos, Rio de Janeiro

All Listed Sponsors

lead

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

OTHER

NCT01889836 - Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos | Biotech Hunter | Biotech Hunter